APAC Meglitinide Market Size
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2018 - 2022 |
| CAGR | 1.70 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
APAC Meglitinide Market Analysis
The Asia-Pacific Meglitinide Market size is estimated at USD 1.62 billion in current year, and is expected to reach USD 1.76 billion by forecat year, growing at a CAGR of 1.70% during the forecast period.
People with Covid-19 had a statistically greater incidence of type 2 diabetes and other kinds of diabetes in the Asia-Pacific region. Individuals with no history of diabetes who recovered from SARS-CoV-2 infections have been reported to develop insulin resistance and reduced insulin secretion. It has been proposed that integrated rather than disease-specific methods are needed for post-Covid syndrome diagnosis and therapy.
Meglitinides are a type of non-sulfonylurea insulin secretagogues with a fast onset and short duration of action. They stimulate glucose-sensitive first-phase insulin release, lowering the risk of hypoglycemia. Meglitinides cause the body to release more insulin in people with type 2 diabetes, who have chronically high blood sugar levels. The World Health Assembly agreed on a Resolution to strengthen diabetes prevention and control in May 2021. It recommends actions such as increasing access to diabetes medicines and health products and assessing the feasibility and potential value of establishing a web-based tool to share information relevant to market transparency for diabetes medicines and health products.
The number of people with diabetes, especially type 2 diabetes, has increased rapidly in recent decades in Asian countries. Over 70% of the world's diabetic population lives in developing countries. The Asia-Pacific region is expected to witness significant growth with an aging population and increasing prevalence of diabetes, mainly due to increasing stress levels. A sedentary lifestyle, smoking, and excessive alcohol consumption, which raises blood sugar levels in the body, are contributing to the growth of this market. In addition, the manufacturing bases of certain anti-diabetic drug companies in the region also fueled the market growth. However, ever-increasing drug costs are considered to be one of the biggest restraining factors for the market. According to the OECD iLibrary, about 227 million people live with type 2 diabetes in the Asia-Pacific region, about half of whom remain undiagnosed and are unaware of the development of long-term complications. According to the International Diabetes Federation, by 2021, 90 million adults aged 20-79 will have diabetes in the Southeast Asia (SEA) region, with 113 million by 2030 and 152 million by 2030. expected to increase in humans. 2045 respectively.
This is driving the demand for Meglitinides in Asia-Pacific, thereby driving the market in focus during the forecast period.
APAC Meglitinide Market Trends
Rising Diabetes Prevalence in Asia-Pacific Region
The Asia-Pacific region witnessed an alarming increase in the prevalence of diabetes in recent years. In developing countries such as China and India, the rate of diabetes is at an all-time high. Patients with diabetes require many daily corrections to maintain normal blood glucose levels, such as oral anti-diabetic medication or ingesting additional carbohydrates, by monitoring their blood glucose levels. Leading manufacturers are focusing on technological innovations and developing advanced products to gain a substantial market share.
Oral anti-diabetic medications are accessible globally and are indicated for usage when treatment escalation for type 2 diabetes is necessary, in addition to lifestyle control. Because of their wide variety of effectiveness, safety, and modes of action, oral medicines are often the first drugs utilized to treat type 2 diabetes. Diabetes medications assist diabetic people in maintaining control of their condition and lowering the risk of diabetes complications. Diabetes patients may need to take diabetes medications for the rest of their life to maintain their blood glucose levels and avoid hypoglycemia and hyperglycemia. Meglitinides are non-sulfonylurea insulin secretagogues with a fast onset and brief duration of action. They promote glucose-sensitive first-phase insulin release, lowering the risk of hypoglycemia. Meglitinides cause the body to release more insulin in people with type 2 diabetes and chronically high blood sugar levels.
The World Health Assembly Resolution 2022 advocated for the integration of diabetes prevention and treatment into primary health care, the creation of pathways for a significant increase in insulin access, the promotion of regulatory convergence and harmonization for diabetes medicines and technologies, and improved diabetes monitoring and surveillance. Furthermore, it entails the WHO advising Member States on ensuring the continuous care of people with diabetes in humanitarian catastrophes. This significant achievement establishes a global mandate for diabetes work for the next decade.
As a result of the reasons above, the studied market is expected to increase throughout the analysis period.
China is Expected to Dominate the Asia-Pacific Meglitinides Market.
According to estimates, one in ten Chinese national residents includes diabetes. Each year, millions of new cases of diabetes are diagnosed in the twenty-first century. However, because many instances are thought to go undiagnosed, it is challenging to determine the exact number of diabetes in China. China is thought to surpass India as the nation with the highest prevalence of diabetes worldwide. China's cities, where traditional eating habits are swiftly vanishing, and economic growth is rising, are where diabetes is most common. The main contributors to this rise in diabetes cases, according to Chinese health experts, are urbanization, higher living standards, and an ageing population. By paying outpatients for more than half of their prescription expenditures, China took measures to cut the costs of treating diabetic and high blood pressure patients, according to the National Health Commission (NHC). More hospitals in China will create National Metabolic Management Centres (MMC) as part of their investigation into a new model of diabetes care, according to a national metabolic disease clinical research centre. Over the past two years, MMCs all around the nation treated more than 200,000 patients, according to data from the National Health Commission, China.
Meglitinides, for example, bind to the sulfonylurea receptor in beta cells (pancreatic insulin-producing cells) but at a different site than sulfonylureas. Meglitinides' interaction with the receptor is less " tight " than sulfonylureas. It results in a much shorter duration of action and a higher blood glucose level required before the drugs produce pancreatic insulin secretion. Currently, two meglitinides are available in the United States: repaglinide (Prandin) and nateglinide (Starlix). Both are approved for use in Type 2 diabetes patients alone and combination with other oral diabetes medications. The main effect of meglitinides is to lower after-meal blood glucose levels, which results in a lower HbA1c (an indicator of blood glucose control over the previous 2-3 months).
Owing to the factors above, the market is expected to grow during the forecast period.
APAC Meglitinide Industry Overview
The Meglitinides market is fragmented, with manufacturers like Novo Nordisk, Glenmark, and Novartis. The manufacturers include a global market presence, which is highly competitive due to generic drug manufacturers' presence.
APAC Meglitinide Market Leaders
Novo Nordisk
Glenmark
Novartis
Kissei
Biocon
*Disclaimer: Major Players sorted in no particular order
APAC Meglitinide Market News
- March 2023: A randomized, open-label, controlled, parallel-group, multicenter trial was conducted to evaluate the efficacy and safety of INS068 once daily (QD) in subjects with type-2 diabetes. It is not adequately controlled with oral antidiabetic drugs compared to insulin Glargine QD for 26+26 weeks.
- January 2023: OXJournal reviewed the effects of meglitinides as a class of oral medications for treating type 2 diabetes, especially in young adults.
APAC Meglitinide Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 Drug
5.1.1 Meglitinides
5.2 Geography
5.2.1 Japan
5.2.2 China
5.2.3 South Korea
5.2.4 India
5.2.5 Australia
5.2.6 Malaysia
5.2.7 Indonesia
5.2.8 Philippines
5.2.9 Thailand
5.2.10 Rest of Asia-Pacific
6. MARKET INDICATORS
6.1 Type-1 Diabetes Population
6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
7.1 Company Profiles
7.1.1 Novo Nordisk
7.1.2 Novartis
7.1.3 Glenmark
7.1.4 Boehringer Ingelheim
7.1.5 Biocon
7.1.6 Kissei Pharmaceuticals
- *List Not Exhaustive
7.2 Company Share Analysis
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
APAC Meglitinide Industry Segmentation
Meglitinide derivatives are oral diabetes medications that help persons with type 2 diabetes mellitus (T2DM) manage their high blood sugar levels with a healthy diet and regular exercise. T2DM is a chronic medical disorder that makes it difficult for the body to manage the amount of sugar in the blood because it does not use insulin as it should. Controlling high blood sugar lowers the chance of heart attack and stroke, kidney disease, blindness, nerve damage, limb loss, and issues with sexual function. The Asia-Pacific Meglitinide Market is segmented by geography (Japan, China, South Korea, India, Australia, Vietnam, Malaysia, Indonesia, Philippines, Thailand, and the rest of Asia-Pacific). The report offers the value (in USD) and volume (in units) for the above segments. We will provide a segment-wise breakdown (value and volume) for all the countries covered under the Table of Contents.
| Drug | |
| Meglitinides |
| Geography | |
| Japan | |
| China | |
| South Korea | |
| India | |
| Australia | |
| Malaysia | |
| Indonesia | |
| Philippines | |
| Thailand | |
| Rest of Asia-Pacific |
APAC Meglitinide Market Research FAQs
What is the current APAC Meglitinide Market size?
The APAC Meglitinide Market is projected to register a CAGR of 1.7% during the forecast period (2024-2029)
Who are the key players in APAC Meglitinide Market?
Novo Nordisk, Glenmark, Novartis, Kissei and Biocon are the major companies operating in the APAC Meglitinide Market.
What years does this APAC Meglitinide Market cover?
The report covers the APAC Meglitinide Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the APAC Meglitinide Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
APAC Meglitinide Industry Report
Statistics for the 2024 APAC Meglitinide market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. APAC Meglitinide analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
